Privately-held Cambridge, USA-based biotech Gensaic announced a potentially lucrative license and discovery collaboration ...
GlobalData on MSN1d
Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic dealNovo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...
Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered ...
MNTN, Inc. ("MNTN"), a technology platform that brings performance marketing to Connected TV, announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange ...
Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...
San Francisco-based 3T Biosciences, an immunotherapy company in the field of solid tumors and other immune-mediated diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback